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Summary 
 
Chronic myelomonocytic leukemia (CMML) is a haematological disease 
currently classified in the category of myelodysplastic syndromes/myeloproliferative 
neoplasm (MDS/MPN) because of its dual clinical and biological presentation. The 
molecular biology of CMML is poorly characterised. We studied a series of 53 CMML 
samples including 31 cases of myeloproliferative form (MP-CMML) and 22 cases of 
myelodysplastic forms (MD-CMML) using array-comparative genomic hybridisation 
(aCGH) and sequencing of 13 candidate genes including ASXL1, CBL, FLT3, IDH1, 
IDH2, JAK2, KRAS, NPM1, NRAS, PTPN11, RUNX1, TET2 and WT1. Mutations in 
ASXL1 and in the genes associated with proliferation (CBL, FLT3, PTPN11, RAS) 
were mainly found in MP-CMML cases. Mutations of ASXL1 correlated with an 
evolution toward an acutely transformed state: all CMMLs that progressed to acute 
phase were mutated and none of the unmutated patients had evolved to acute 
leukaemia. The overall survival of ASXL1 mutated patients was lower than that of 
unmutated patients. 
 
Keywords: chronic myelomonocytic leukaemia, gene mutation, ASXL1, 
prognosis.  
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Chronic myelomonocytic leukaemia (CMML) is a haematopoietic disease 
currently classified by the WHO organization in a mixed category called MDS/MPN 
(myelodysplastic syndromes/myeloproliferative neoplasm) (Vardiman, 2002). Despite 
recent molecular improvements in the classification of myeloid neoplasms, diagnosis 
of CMML is still based on cytological criteria including persistent peripheral 
monocytosis greater than 1 x 109 /L, less than 20% blasts in the blood or bone 
marrow (BM) and bone marrow dysplasia in one or more myeloid lineage. The only 
molecular criterium is the absence of BCR-ABL transcript (Bennett et al, 1982, 
Vardiman, 2002). Because the blast number is a prognostic factor, CMML is divided 
in two types: type 1 with fewer than 5% blasts in the blood and 10% blasts in the 
bone marrow, and type 2 with between 5 to 19% in the blood or 10 to19% in the bone 
marrow (Vardiman, 2002; Vardiman et al,  2009).  
Classification of CMML has always been a matter of debate based on the two 
distinct clinical presentations: dysplastic with symptomatic complications of 
cytopenia, and proliferative with splenomegaly or hepatomegaly. In 1994, on the 
basis of an arbitrary threshold of peripheral leukocyte count (WBC), a dysplastic (<13 
x 109 /L) and a proliferative (> 13 x 109 /L) forms have been recognised by the FAB 
group (Bennett, 1994), which we will call here MD-CMML and MP-CMML, 
respectively. Until recently, neither biologic nor prognostic data allowed the support 
of this distinction except that MP-CMML seemed to have more RAS mutations 
(Padua et al, 1988; Padua et al, 1998). Recently, new molecular alterations have 
been described in CMML. We and others have showed a high frequency of RUNX1 
and TET2 mutations (Gelsi-Boyer et al, 2008; Kosmider et al, 2009b; Kuo et al, 
2009). Mutations of TET2 and CBL occur in 50% (Kosmider et al, 2009b) and 5% 
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(Makishima et al, 2009) of CMML cases, respectively. Recently, we described exon 
12 mutations of ASXL1 with a frequency about 44% (Gelsi-Boyer et al, 2009). 
Currently, the impact of these alterations remains to be determined and the biological 
and clinical presentations are still heterogeneous and benefit from opposite 
therapeutics: cytotoxic in the MP form, haematopoietic growth factors in the MD form.  
We propose here a comprehensive study of molecular alterations in a series of 
53 CMMLs using genome-wide, high-density array-comparative genomic 
hybridisation (aCGH) and exon-coding sequencing of 13 candidate genes. We show 
that ASXL1 mutations are associated with MP-CMML and that MP-CMMLs have 
overall more alterations. Most importantly, we show that mutations in ASXL1 
correlate with acute transformation of CMML and that the overall survival rate is 
lower in ASXL1 mutated patients than in unmutated patients.  
 
 
Patients and methods 
 
Patients and samples 
A series of consecutive bone marrow samples obtained from 53 patients, who 
all signed an informed consent, were collected. Among these were 31 MP-CMMLs 
and 22 MD-CMMLs as initially defined by the FAB group with a leukocyte count 
superior or inferior to 13 x 109 /L, respectively. The median age and leukocytosis 
were 74 years and 30 x 109 /L respectively in the MP-CMML group and 76.5 years 
and 9 x 109 /L respectively in the MD-CMML group. The main clinical and biological 
data of the 53 samples are presented in Supplementary Table I. Most of the 
samples (39 cases) were obtained from patients newly diagnosed. Fourteen were 
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known for a CMML either in therapeutic abstention (9 cases) or under symptomatic 
treatment (5 cases). Most patients of the latter group (12/14) were at more of one 
year after diagnosis. Six patients had received prior chemotherapy or radiotherapy 
for an independent solid tumour. A normal karyotype was observed in 40 patients (20 
MP-CMMLs and 20 MD-CMMLs); a del(20q)(q11q13) was found in 3 patients (2 MP-
CMMLs and 1 MD-CMML); a trisomy of a commonly affected chromosome (8, 19, 21) 
was encountered in 4 MP-CMMLs. One MD-CMML had an 11q inversion, one MP-
CMML had a t(10;11)(p12;p15) and one MP-CMML had a t(1;3)(p36;q21). Nucleic 
acid extraction was done as previously described (Gelsi-Boyer et al,  2008). 
 
Array comparative genomic hybridisation (aCGH) 
aCGH was done on all samples but two (HD-0397, HD-0715). Some of the 
results have been published on 38 cases (Gelsi-Boyer et al,  2008; Gelsi-Boyer et al, 
2009). Genomic imbalances were analysed by aCGH using 244K CGH Microarrays 
(Hu-244A, Agilent Technologies, Massy, France) as previously described (Adélaïde  
et al 2007; Etienne et al, 2007). Scanning was done with Agilent Autofocus Dynamic 
Scanner (G2565BA, Agilent Technologies). Data analysis was done as previously 
described (Murati et al, 2003; Barrett et al 2004,) and visualised with CGH Analytics 
3.4 software (Agilent Technologies). Extraction data (log2 ratio) was done with CGH 
analytics while normalised and filtered log2 ratios were obtained from « Feature 
extraction » software (Agilent Technologies). Copy number changes were 
characterised as reported (Adélaïde et al,  2007; Etienne et al,  2007).  
 
DNA sequencing  
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Polymerase chain reaction (PCR) and direct sequencing were done using 
standard conditions with gene-specific primers designed to amplify coding sequence 
of ASXL1 (exon 12), CBL (exons 8, 9), FLT3 (exons 14, 15, 20), IDH1/2 (exon 4), 
JAK2 (exon 14), K, NRAS (exons 1, 2), NPM1 (exon 12), PTPN11 (exons 3, 11), 
RUNX1 (exons 1 to 8), TET2 (exons 3 to 11) and WT1 (exons 7, 9) as previously 
described (Gelsi-Boyer et al, 2008; Gelsi-Boyer et al, 2009, Kosmider et al 2009a, 
Carbuccia et al, 2010; Kosmider, et al 2009b). Primers are described in Gelsi-Boyer 
et al. (2008) and Rocquain et al. (2010b). Most PCR amplifications were done in a 
total volume of 25 µl PCR mix containing at least 10 ng template DNA, Taq buffer, 
200 µmol of each deoxynucleotide triphosphate, 20 pmol of each primer and 1 unit of 
Hot Star Taq (Qiagen). PCR amplification conditions were as follows: 95°C 10 min; 
95°C 30 sec, variable temperature 30 sec, 72°C 45 sec for 30 cycles; 72°C 10 min. 
PCR products were purified using Millipore plate MSNU030. Two microliters of the 
purified PCR products were used for sequencing using the Big Dye terminator v1.1 
kit (Applied Biosystems). After G50 purification, sequences were loaded on an ABI 
3130XL automat (Applied Biosystems). The sequence data files were analysed using 
the SeqScape software and all mutations were confirmed on an independent PCR 
product. 
 
Statistical Analysis 
Clinical and biological factors were taken at the time of sampling whose date 
corresponds to the search for molecular alterations. The different quantitative 
biological variables were compared by the Student test (t-test) and prevalence of 
mutations or alterations detected by karyotype or aCGH by the Chi-square test. 
Overall survival was defined by the time from the date of diagnosis to the date of 
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death. Patients still alive were right censored at the date of last contact. “Time-to-
AML” was defined by the time from the date of sampling to the date of acute 
transformation. Patients still alive were right censored at the date of last contact. In 
time-to-AML analysis, deaths occurring before AML transformation were treated as 
competing event. To investigate the association between outcome and the different 
covariates, univariate analysis was done using Log-Rank, Wald, and Gray tests. Cox 
Proportional Hazard and Fine and Gray models were used in a multivariate 
approach. Cumulative incidences of AML transformations were estimated by the 
Prentice method. All statistical tests were two-sided at the 5% level of significance. 
 
 
Results  
 
aCGH profiles of CMML 
We established the aCGH profiles of 51 of the 53 CMML cases. Results are 
summarized in Table I. aCGH revealed alterations that were observed by 
conventional cytogenetics (9/51) except for 3 patients with balanced translocations 
(HD-0201, HD-0316, HD-0178), and for case HD-0367 with a del(20)(q11q13) for 
which aCGH did not show a frank deletion at 20q probably due to the low number of 
affected cells. For nine cases (17%) aCGH detected rare and limited losses or gains, 
not visible on the karyotype. They affected very few genes, as previously described 
(Gelsi-Boyer et al, 2008; Adélaïde et al, 2010; Rocquain et al, 2010a), including 
some with known tumour suppressor function and leukaemogenic activity (NF1, RB1 
and TET2). In 70% of cases (36/51) no copy number aberrations were observed. 
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Mutations in candidate genes are frequent in CMML 
We studied coding sequences of 13 genes on the 53 cases (Table I). Some 
results have been previously published (Gelsi-Boyer et al, 2008; Gelsi-Boyer et al, 
2009; Kosmider et al, 2009b). In 25 cases (49%) we found 20 frameshift (including 7 
times the same p.Gly646Trpfsx12) and 5 nonsense mutations in ASXL1 exon 12. For 
three patients (HD-0228, HD-0328, HD-0370), we could demonstrate that the 
mutation was acquired because the mutation was absent from buccal smear DNA 
(not shown). CBL exon 8 mutations were found in about 10% of cases (5/47); one 
case (HD-0223) had a homozygous mutation. One case (HD-0367) had an internal 
tandem duplication of FLT3. We found 5 IDH mutations in 48 cases (10%); all were in 
IDH2 (4 times the same p.Arg140Gln). Seven patients out of the 53 cases (13%) had 
a K or NRAS mutation. We previously examined the sequence of exons 3 and 13 of 
the PTPN11 gene and mutations were found in two cases (Gelsi-Boyer et al, 2008). 
Twelve out of 53 patients (21%) were mutated for RUNX1 and 36% of patients were 
mutated for TET2. No mutation was found in NPM1, JAK2 and WT1. On the basis of 
small deletions detected by aCGH and spanning only few genes, we searched for 
mutations in an additional set of candidate genes: ASXL2, BRAF, CBFB, CTNNB1, 
KDM3B, KDM6A/UTX, KDM6B, NFIA, PYGO1, SPI1, RAF1, and TET3 but failed to 
find any mutations (unpublished data) except in one patient (HD-0398) for which a 
mutation in NFIA exon 2 was found and previously reported (Bernard et al,  2008). 
 
MP- and MD-CMMLs show quantitative differences in molecular alterations 
Genomic alterations detected by conventional cytogenetics or aCGH were 
different in MP- and MD-CMML (Table I): 15 out of 31 MP-CMMLs and 4 out of 22 
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MD-CMMLs showed alterations. MP-CMMLs had more genomic alterations than MD-
CMMLs (p=0.049).  
We compared the prevalence of the mutated genes in MP and MD-CMML. 
Nineteen of the 25 ASXL1 mutations were found in 30 MP-CMMLs vs 6 in 22 MD-
CMMLs. Mutations in ASXL1 but not in RUNX1 or TET2 were more frequent in MP 
than in MD-CMMLs (p=0.03) (Table I). No difference was observed between the two 
forms for CBL, FLT3, IDH1/2, PTPN11, RAS, RUNX1 or TET2. No RAS pathway 
mutation (RAS and PTPN11) was observed in MD-CMMLs. Mutations in proliferation-
associated genes CBL, FLT3, KRAS, NRAS and PTPN11 were mutually exclusive 
and taken as a whole significantly associated with MP-CMML (14/123 versus 1/91; 
p=0.008). Overall, the number of mutations (ASXL1 and proliferation genes) was 
higher in MP than in MD-CMMLs (p=0.018). 
Altogether, molecular events (mutations and genomic alterations) were more 
frequent in MP-CMMLs (69/273 events) than in MD-CMMLs (26/172) (p=0.0018). 
 
Correlations between ASXL1 mutation and clinical and biological features in 
CMML 
The main clinical and biological features of 51 CMML cases were examined 
with respect to ASXL1 mutations (Table II). The presence of an ASXL1 mutation was 
associated with higher WBC (30 x 109 /L vs 15 x 109 /L) (p=0.006), higher blood 
(p=0.005) and bone marrow monocytosis (p=0.04) and with lower level of blood 
haemoglobin (p=0.03). No difference was noted in mean cell volume, blood count of 
neutrophils and platelets, or bone marrow blasts. In MP-CMMLs, ASXL1 mutation 
correlated with a lower level of haemoglobin (p=0.03) and platelet count (p=0.002) 
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and with a higher monocytosis (p=0.04). In MD-CMMLs, no correlations with ASXL1 
mutation were observed. 
Among ASXL1 mutated cases (25/51), eleven (9 MP and 2 MD) had evolved 
to acute transformation (Table II). For one case (HD-0398) DNA of the acute phase 
was available; we looked for the ASXL1 mutation and found the same alteration (not 
shown). In contrast, no acute transformation was observed in the unmutated cases. 
In other words, all transformed cases had an ASXL1 mutation but not all ASXL1 
mutated cases had progressed to AML. ASXL1 mutation and acute transformation 
were correlated (p=0.0005). Patient HD-0316 had progressed to acute phase but was 
not included in the 51 patients since we could not determine the ASXL1 status 
because of lack of material at either stage.  
Overall survival (median follow-up of 29.5 months) was analysed for the 53 
patients. Median overall survival was 27.6 months (Fig 1A). ASXL1 status could be 
determined at the time of diagnosis for 51 patients. Kaplan-Meier analysis showed a 
lower overall survival rate in the ASXL1 mutated patients (Fig 1B). With respect to 
MP/MD form, only a trend to a better survival of the MD patients was observed (not 
shown). Within MP-CMML patients, cases mutated for ASXL1 had a poorer survival 
than the unmutated cases (not shown). We determined the cumulative incidence of 
AML (Fig 1C) and observed that all the patients who developed AML did so within 
two years and that ASXL1 mutation had a strong impact on AML incidence (Fig 1D). 
We did the same analysis for TET2 mutational status. In contrast to ASXL1, TET2 
had no impact on overall survival (not shown). Given the low number of events for 
the other genes we did not look for any other clinical or biological correlation.  
Univariate analysis of time-to-AML was done on 50 patients using as variables 
ASXL1 and TET2 mutational status and MP/MD form, monocytosis, blast count in 
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bone marrow, anemia, and CMML1/2 type. The following variables showed 
significance: ASXL1 status (p=0.0002; 24-months incidence: 0.48, confidence 
interval 95: [0.26-0.71]), monocytosis in peripheral blood (p=0.042; 24-months 
incidence: 0.25, confidence interval 95: [0.12-0.38]; hazard ratio: 1.05, confidence 
interval 95: [1-1.09]), blast count (p=0.0011; 24-months incidence: 0.25, confidence 
interval: [0.12-0.38]; hazard ratio: 1.18, confidence interval: [1.07-1.3]) and CMML1/2 
(p=0.014; CMML1 24-months incidence: 0.16, confidence interval: [0.04-0.28], 
hazard ratio: 1; CMML2 24-months incidence: 0.58, confidence interval: [0.23-0.93], 
hazard ratio: 3.96, confidence interval: [1.34-11.7]). A multivariate analysis of time-to-
AML was done using Cox regression model and the same variables. Only the ASXL1 
status retained significant prognostic impact (p<0.0001). Thus, in CMML, ASXL1 
mutation is an unfavourable prognostic factor for overall survival and progression to 
AML.  
 
 
Discussion  
 
We established the genomic profiles of a series of 53 CMMLs by using aCGH 
and sequencing of 13 candidate genes.  
 
ASXL1 is the most frequently mutated gene in CMML  
In more than two-thirds of cases aCGH profiles did not show any copy number 
aberrations. In few cases, small copy number aberrations were indicative of genes 
known (NF1, RB1, TET2) or suspected (SH3KPB1, RAD21) (Adélaïde et al, 2010; 
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Rocquain et al, 2010a) to be involved in leukaemogenesis. MP-CMMLs had more 
genomic alterations than MD-CMMLs. 
We studied 13 candidate genes. We classified these genes into three groups. 
The first group comprised five known and potential tumour suppressors and 
transcription factors, the second group six genes associated with kinase activity, 
signalling pathways and proliferation, and the third group the two IDH genes. 
Hypothetically, CMML could result from a combination of mutation(s) in each of these 
groups, and perhaps more yet-to-be discovered mutations. Overall, mutations of 
ASXL1, RUNX1 and TET2 were prominent in particular in MP-CMMLs but the 
difference between the two forms was not statistically significant for the three genes 
taken as a whole (p=0.19). Mutations in these three genes were not mutually 
exclusive. This is in contrast to what we observed in myelodysplastic syndromes 
(MDS) and acute myeloid leukaemia where RUNX1 and TET2 mutations were 
mutually exclusive but could each be associated with ASXL1 mutations (Rocquain et 
al., 2010b). We have no explanation for this observation. ASXL1 mutations are found 
in all myeloid neoplasms (Carbuccia et al, 2009; Gelsi-Boyer et al, 2009; Carbuccia 
et al, 2010; Kosmider et al, 2009a; Boultwood et al, 2010a; Boultwood et al, 2010b; 
Sugimoto et al, 2010; Tefferi, 2010). In the present study ASXL1 appeared as the 
most frequently mutated gene in CMML, as it is in MDSs (Boultwood et al, 2010a; 
Rocquain et al, 2010b). In MDSs, ASXL1 mutations are found in high-risk cases.  
As previously observed (Gelsi-Boyer et al, 2008) mutations in the second 
group of “proliferation” genes were mutually exclusive. The frequency of mutations of 
CBL was in the range of what was observed recently (Makishima et al, 2009). With 
two exceptions (a CBL mutation and an NF1 deletion detected by aCGH), mutations 
in these genes were a hallmark of MP-CMML and may explain the proliferative 
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features of this form. In agreement, it has recently been shown that JAK2 mutations 
are associated with MP-CMML (Ricci et al, 2010). However, in our series we did not 
find any JAK2 mutation. Overall, the number of mutations (ASXL1 and proliferation 
genes) was higher in MP-CMML than in MD-CMML. This is a molecular basis to the 
separation of CMML in MP and MD forms initially defined by the FAB group. 
However, the equal number of mutations of RUNX1 and TET2 in both forms 
suggests a common mechanism of oncogenesis.   
 
ASXL1 mutation is associated with poor prognosis and acute transformation of 
CMML 
The MP and MD classification may have a molecular basis (Gelsi-Boyer et al, 
2007; this work) but had no significant impact on prognosis in our series. Several 
studies have similarly found that this classification does not by itself offer enough 
prognostic information (Germing et al, 1998; Nosslinger et al, 2001; Gonzalez-
Medina et al, 2002). We have here shown that, in contrast, ASXL1 mutation is 
associated with both poor overall survival and acute transformation. In our series, no 
unmutated cases had evolved to acute phase whereas the cases that had 
progressed to acute leukaemia were all mutated (except for one case for which we 
could not determine the ASXL1 status). A multivariate analysis of time-to-AML 
including ASXL1 mutation and other factors revealed that only ASXL1 status has 
significant impact. However, ASXL1 status was not significant in multivariate analysis 
of overall survival (not shown), perhaps because of the limited number of cases or 
the existence of confounding factors such as deaths by other causes. Some mutated 
cases had not progressed to acute phase. This may be because patients had died 
before experiencing acute leukaemia. This may have been the case for patients HD-
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0230 and HD-0660, whose ASXL1 mutated CMML progressed from CMML1 to 
CMML2. For mutated patients still alive it could be a question of time. If this were the 
case ASXL1 mutation could be used to predict the risk of progression of CMML to 
acute leukaemia. In contrast, TET2 mutations had no impact. A previous study had 
found prognostic impact of TET2 mutation but only in CMML1 (Kosmider et al, 
2009b).  
ASXL1 mutation is associated with aggressive forms in other myeloid 
disorders, including high-risk MDSs, primitive myelofibrosis (Carbuccia et al, 2009), 
secondary acute myeloid leukaemias (Carbuccia et al, 2010). If confirmed on a larger 
series the data would endow ASXL1 with such a prognostic value that its mutational 
status may be systematically determined in hospital setting and that the management 
of patients with mutation may be adapted. It could also be interesting to classify 
CMMLs studied in clinical trials according to ASXL1 status.   
 
 
Author contributions 
AM, CA, HZ HF, ZT, MN, MJM, and NV selected the cases, and provided and 
reviewed the clinical and biological data. JA and MC generated and analyzed the 
aCGH data. VT, JR, and NC generated and analyzed the sequencing data. BE and 
PF did the statistical analyses. VGB and DB supervised the study and wrote the 
manuscript. All authors approved the study and the manuscript. 
 
 
Acknowledgements 
We are grateful to the patients who accepted to participate in this study. The 
Page 15 of 25 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
work was supported by Inserm and Institut Paoli-Calmettes.  
 
 
References 
Adélaïde, J., Finetti, P., Bekhouche, I., Repellini, L., Geneix, J., Sircoulomb, F., 
Charafe-Jauffret, E., Cervera, N., Desplans, J., Parzy, D., Schoenmakers, E., 
Viens, P., Jacquemier, J., Birnbaum, D., Bertucci, F. & Chaffanet, M. (2007) 
Integrated profiling of basal and luminal breast cancers. Cancer Res, 67, 
11565-11575. 
Adélaïde, J., Rocquain, J., Gelsi-Boyer, V., Carbucci, N., Birnbaum, D.J., 
Mozziconacci, MJ., Vey, N., Birnbaum, D. & Chaffanet, M. (2010) Gain of 
CBL-interacting protein: a possible alternative to CBL mutations in 
myelodysplastic syndromes and chronic myelomonocytic leukemia.  
Leukemia, 24, in press.  
Barrett, M.T., Scheffer, A., Ben-Dor, A., Sampas, N., Lipson, D., Kincaid, R., Tsang, 
P., Curry, B., Baird, K., Meltzer, P.S., Yakhini, Z., Bruhn, L. & Laderman, S. 
(2004) Comparative genomic hybridization using oligonucleotide microarrays 
and total genomic DNA. Proc Natl Acad Sci U S A, 101, 17765-17770. 
Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & 
Sultan, C. (1982) Proposals for the classification of the myelodysplastic 
syndromes. Br J Haematol, 51, 189-199. 
Bennett JM, C.D., Daniel MT, et al (1994) The chronic myeloid leukaemias: 
guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, 
and chronic myelomonocytic leukaemia. Proposals by the French-American-
British Cooperative Leukaemia Group. Br J Haematol, 84, 746-754. 
Bernard, F., Gelsi-Boyer, V., Murati, A., Giraudier, S., Trouplin, V., Adélaïde, J., Rey, 
J., Olschwang, S., Vainchenker, W., Chaffanet, M., Vey, N., Mozziconacci, 
M.J. & Birnbaum, D. (2008) Alterations of NFIA in chronic malignant myeloid 
diseases. Leukemia. 
Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-
Santamaria, C., Calasanz, M.J., Larrayoz, M.J., Garcia-Delgado, M., 
Giagounidis, A., Malcovati, L., Della Porta, M.G., Jadersten, M., Killick, S., 
Hellstrom-Lindberg, E., Cazzola, M. & Wainscoat, J.S. Frequent mutation of 
the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and 
in acute myeloid leukemia. Leukemia, 24, 1062-1065. 
Boultwood, J., Perry, J., Zaman, R., Fernandez-Santamaria, C., Littlewood, T., 
Kusec, R., Pellagatti, A., Wang, L., Clark, R.E. & Wainscoat, J.S. High-density 
single nucleotide polymorphism array analysis and ASXL1 gene mutation 
screening in chronic myeloid leukemia during disease progression. Leukemia, 
24, 1139-1145. 
Carbuccia, N., Murati, A., Trouplin, V., Brecqueville, M., Adélaïde, J., Rey, J., 
Vainchenker, W., Bernard, O.A., Chaffanet, M., Vey, N., Birnbaum, D. & 
Mozziconacci, M.J. (2009) Mutations of ASXL1 gene in myeloproliferative 
neoplasms. Leukemia, 23, 2183-2186. 
Carbuccia, N., Trouplin, V., Gelsi-Boyer, V., Murati, A., Rocquain, J., Adélaïde, J., 
Olschwang, S., Xerri, L., Vey, N., Chaffanet, M., Birnbaum, D. & Mozziconacci, 
Page 16 of 25British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
M.J. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute 
myeloid leukemias. Leukemia, 24, 469-473. 
Etienne, A., Carbuccia, N., Adélaïde, J., Bekhouche, I., Remy, V., Sohn, C., Sainty, 
D., Gastaut, J.A., Olschwang, S., Birnbaum, D., Mozziconacci, M.J. & 
Chaffanet, M. (2007) Rearrangements involving 12q in myeloproliferative 
disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genet 
Cytogenet, 176, 80-88. 
Gelsi-Boyer, V., Cervera, N., Bertucci, F., Trouplin, V., Remy, V., Olschwang, S., 
Chaffanet, M., Vey, N., Mozziconacci, M.J. & Birnbaum, D. (2007) Gene 
expression profiling separates chronic myelomonocytic leukemia in two 
molecular subtypes. Leukemia, 21, 2359-2362. 
Gelsi-Boyer, V., Trouplin, V., Adélaïde, J., Aceto, N., Remy, V., Pinson, S., 
Houdayer, C., Arnoulet, C., Sainty, D., Bentires-Alj, M., Olschwang, S., Vey, 
N., Mozziconacci, M.J., Birnbaum, D. & Chaffanet, M. (2008) Genome profiling 
of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 
genes. BMC Cancer, 8, 299-315. 
Gelsi-Boyer, V., Trouplin, V., Adélaïde, J., Bonansea, J., Cervera, N., Carbuccia, N., 
Lagarde, A., Prebet, T., Nezri, M., Sainty, D., Olschwang, S., Xerri, L., 
Chaffanet, M., Mozziconacci, M.J., Vey, N. & Birnbaum, D. (2009) Mutations of 
polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic 
myelomonocytic leukaemia. Br J Haematol, 145, 788-800. 
Germing U, G.N., Minning H, Heyll A, Aul C. (1998) Problems in the classification of 
CMML--dysplastic versus proliferative type. Leuk Res, 22, 871-878. 
Germing U, S.C., Knipp S, Kuendgen A, Giagounidis A, Hildebrandt B et al. (2007) 
Chronic myelomonocytic leukemia in the light of the WHO proposals. 
haematologica, 92, 974-977. 
Gonzalez-Medina I, B.J., Torrequebrada A, Lopez A, Vallespi T & Massague I. 
(2002) Two groups of chronic myelomonocytic leukaemia: myelodysplastic 
and myeloproliferative. Prognostic implications in a series of a single center. 
Leuk Res, 26, 821-824. 
Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., 
Viguie, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., Vey, N., Hunault-Berger, 
M., Fenaux, P., Mansat-De Mas, V., Delabess , E., Guardiola, P., Lacombe, 
C., Vainchenker, W., Preudhomme, C., Dreyfus, F., Bernard, O.A., Birnbaum, 
D. & Fontenay, M. (2009a) TET2 mutation is an independent favorable 
prognostic factor in myelodysplastic syndromes (MDSs). Blood, 114, 3285-
3291. 
Kosmider, O., Gelsi-Boyer, V., Ciudad, M., Racoeur, C., Jooste, V., Vey, N., 
Quesnel, B., Fenaux, P., Bastie, J.N., Beyne-Rauzy, O., Stamatoulas, A., 
Dreyfus, F., Ifrah, N., de Botton, S., Vainchenker, W., Bernard, O.A., 
Birnbaum, D., Fontenay, M. & Solary, E. (2009b) TET2 gene mutation is a 
frequent and adverse event in chronic myelomonocytic leukemia. 
haematologica, 94, 1676-1681. 
Kosmider, O., Gelsi-Boyer, V., Slama, L., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., 
Hunault-Berger, M., Slama, B., Vey, N., Lacombe, C., Solary, E., Birnbaum, 
D., Bernard, O.A. & Fontenay, M. Mutations of IDH1 and IDH2 genes in early 
and accelerated phases of myelodysplastic syndromes and 
MDS/myeloproliferative neoplasms. Leukemia, 24, 1094-1096. 
Kuo, M.C., Liang, D.C., Huang, C.F., Shih, Y.S., Wu, J.H., Lin, T.L. & Shih, L.Y. 
(2009) RUNX1 mutations are frequent in chronic myelomonocytic leukemia 
Page 17 of 25 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
and mutations at the C-terminal region might predict acute myeloid leukemia 
transformation. Leukemia, 23, 1426-1431. 
Makishima, H., Cazzolli, H., Szpurka, H., Dunbar, A., Tiu, R., Huh, J., Muramatsu, H., 
O'Keefe, C., Hsi, E., Paquette, R.L., Kojima, S., List, A.F., Sekeres, M.A., 
McDevitt, M.A. & Maciejewski, J.P. (2009) Mutations of e3 ubiquitin ligase cbl 
family members constitute a novel common pathogenic lesion in myeloid 
malignancies. J Clin Oncol, 27, 6109-6116. 
Murati, A., Adélaïde, J., Popovici, C., Mozziconacci, M.J., Arnoulet, C., Lafage-
Pochitaloff, M., Sainty, D., Birnbaum, D. & Chaffanet, M. (2003) A further case 
of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement 
and MOZ-NCOA2 gene fusion. Int J Mol Med, 12, 423-428. 
Nosslinger, T., Reisner, R., Grüner, H., Tüchler, H., Nowotny, H., Pittermann, E. & 
Pfeilstöcker M. (2001) Dysplastic versus proliferative CMML--a retrospective 
analysis of 91 patients from a single institution. Leuk Res, 25, 741-747. 
Onida, F. (2002) pronostics factors in chronic myelomonocytic leukemia: a 
retrospective analysis of 213 patients. Blood, 99, 840-849. 
Padua, R.A., Carter, G., Hughes, D., Gow, J., Farr, C., Oscier, D., McCormick, F., 
Jacobs, A. (1988) RAS mutations in myelodysplasia detected by amplification, 
oligonucleotide hybridization, and transformation. Leukemia, 2, 503-510. 
Padua, R.A., Guinn, B.A., Al-Sabah, A.I., Smith, M., Taylor, C., Pettersson, T., Ridge, 
S., Carter, G., White, D., Oscier, D., Chevret, S. & West, R. (1998) RAS, FMS 
and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year 
follow-up. Leukemia, 12, 887-892. 
Ricci, C., Fermo, E., Corti, S., Molteni, M., Faricciotti, A., Cortelezzi, A., Lambertenghi 
Deliliers, G., Beran, M. & Onida, F. RAS mutations contribute to evolution of 
chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res, 
16, 2246-2256. 
Rocquain, J., Gelsi-Boyer, V., Adélaïde, J., Murati, A., Carbuccia, N., Vey, N., 
Mozziconacci, MJ., Birnbaum, D. & Chaffanet, M. (2010a) Alteration of 
cohesin genes in myeloid diseases. Am J Hematol, in press. 
Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, 
Z., Olschwang, S., Vey, N., Birnbaum, D., Gelsi-Boyer, V.& Mozziconacci, MJ. 
(2010b) Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, 
KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic 
syndromes and acute myeloid leukemias. BMC Cancer, in press.  
Sugimoto, Y., Muramatsu, H., Makishima, H., Prince, C., Jankowska, A.M., Yoshida, 
N., Xu, Y., Nishio, N., Hama, A., Yagasaki, H., Takahashi, Y., Kato, K., 
Manabe, A., Kojima, S. & Maciejewski, J.P. (2010) Spectrum of molecular 
defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Br J 
Haematol, 150, 83-87. 
Tefferi, A. (2010) Novel mutations and their functional and clinical relevance in 
myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and 
IKZF1. Leukemia, 24, 1128-1138. 
Vardiman J-W, H.N.-L. & Brunning R-D (2002) the world health classification (WHO) 
of myeloid neoplasms, Blood, 100, 2292-2302. 
Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., 
Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, 
C.D. (2009) The 2008 revision of the WHO classification of myeloid 
neoplasms and acute leukemia: rationale and important changes. Blood, 114, 
937-951. 
Page 18 of 25British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
 
Page 19 of 25 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Table I. Mutations of candidate genes in a series of CMML.  
 
Samples are separated according to the white blood cell count: MP-CMML with WBC > 13x109/L 
and MD-CMML with WBC < 13x109/L. 
hom: homozygous; nc : verified as not constitutional 
na: non available 
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Table II. Clinical and biological features of ASXL1 mutated and 
unmutated CMML patients. 
     
CMML Number of patients ASXL1 mutated ASXL1 unmutated p value 
Sex ratio 51 3.16 1.27 0.23 
Age: median (range) 51 74 (46-88) 71 (41-88) 0.39 
Leukocyte count: median (range) 51 30 (6-188) 15 (2.8-26.4) 0.006 
Haemoglobin level (g/dL): median (range) 50 10 (8.1-14.1) 12.5 (7.4-16.2) 0.03 
MCV: median (range) 35 92 (86-106) 93 (79-101) 0.33 
Neutrophil count (G/L): median (range) 41 15 (1.5-41) 2 (0.1-12.9) 0.07 
Blood monocyte count (G/L): median (range) 50 4.65 (1-60) 2 (1-46) 0.005 
Platelets count (G/L): median (range) 50 117.5 (34-420) 208 (39-660) 0.07 
Bone marrow blasts (%): median (range) 51 7 (2-18) 6 (1-14) 0.11 
Bone marrow monocytes (%): median 
(range) 50 20 (6-35) 15 (3-45) 0.04 
MP-CMML 30 19 11 
MD-CMML 21 6 15 
0.03 
No acute transformation 51 14 26 
Acute transformation 51 11 0 
0.0005 
MP-CMML Number of patients ASXL1 mutated ASXL1 unmutated p value 
Sex ratio   2.8 0.8  0.25 
Age: median (range) 30 74 (55-88) 70.5 (42-87) 0.13 
Leukocyte count: median (range) 30 35 (6-188) 17 (15-26.5) 0.08 
Haemoglobin level (g/dL): median (range) 29 11 (8.1-12.5) 11.5 (8.5-15.2) 0.03 
MCV: median (range) 21 92 (80-106) 88.5 (74-101) 0.11 
Neutrophil count (G/L): median (range) 26 25 (7-41) 10 (7-12.9) 0.54 
Blood monocyte count (G/L): median (range) 30 10 (1-60) 4.5 (1.2-46) 0.04 
Platelets count (G/L): median (range) 29 118 (34-420) 272 (57-660) 0.002 
Bone marrow blasts (%): median (range) 30 7 (2-16) 6 (2-14) 0.54 
Bone marrow monocytes (%): median 
(range) 29 25 (6-35) 14 (3-45) 0.16 
MD-CMML Number of patients ASXL1 mutated ASXL1 unmutated p value 
Sex ratio 21 5 1.8 0.75 
Age: median (range) 21 76.5 (46-83) 75 (41-88) 0.9 
Leukocyte count: median (range) 21 8.9 (4-12) 7.1 (2.8-12.8) 0.6 
Haemoglobin level (g/dL): median (range) 21 12 (8.9-14.1) 14 (7.4-16.2) 0.77 
MCV: median (range) 13 89 (86-100) 93.5 (91-101) 0.46 
Neutrophil count (G/L): median (range) 19 5 (1.5-7) 7.1 (0.1-7.7) 0.15 
Blood monocyte count (G/L): median (range) 21 1.3 (1-4.5) 1.4 (1-2.6) 0.55 
Platelets count (G/L): median (range) 21 122 (43-414) 130 (39-399) 0.5 
Bone marrow blasts (%): median (range) 21 7 (4-18) 5 (4-13) 0.2 
Bone marrow monocytes (%): median 
(range) 21 16 (10-20) 15 (10-13) 0.83 
MCV: mean cell volume; In bold: significant p value     
Page 21 of 25 British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
Legends to the figure. 
 
Fig 1. Kaplan-Meier overall survival curves for all CMML patients (A) and 
according to ASXL1 mutational status (B). The number of patients at risk over time is 
shown beneath each panel. (C) Cumulative incidence of progression to acute 
myeloid leukaemia for all patients (C) and according to ASXL1 mutational status (D).  
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Table I. Mutations of candidate genes in a series of CMML. 
Case Sex/Age (years) Diagnosis
RUNX1 
(exons 1-8)
TET2 
(exons 3-11)
ASXL1
(exon 12)
NPM1
(exon 12)
WT1 
(exons 7, 9)
CBL 
(exons 8,9)
FLT3 
ITD/TKD
JAK2 
(V617F)
KRAS
(exons 1, 2)
NRAS
(exons 1, 2)
PTPN11 
(exons 3, 13)
IDH1 
(exon 4)
IDH2 
(exon 4)
Number of 
altered genes Karyotype aCGH
HD-0176 M/42 MP-CMML1 no no no no no no no no no no no no no 0 46,XY[20] gain 7p21 (AHR), Xp22 (SH3KBP1)
HD-0182 F/74 MP-CMML1 no no no no no no no no no p.Gly12Asp no no no 1 45, X, -X?c[20]  loss X 
HD-0200 M/71 MP-CMML1 no no no no no no no no p.Ala146Val no no no no 1 46,XY[20] no CNA
HD-0201 M/87 MP-CMML1 no no p.Leu1266HisfsX9 no no no no no p.= p.Ala157Gly no no no 2 46,XY,t(10;11)(p12;p15)[13]/46,XY[7] no CNA
HD-0223 M/85 MP-CMML1 no splicing defect p.Arg1068X no no p.Phe418Ser (hom) no no no no nd no no 3 46,XY[20] loss 13q14 (RB1), 15q21, 15q22 (DAPK2), gain Xp22
HD-0228 M/70 MP-CMML1 no p.Trp1198X p.Thr836LeufsX2 (nc) no no no no no p.Gly12Ser no no no no 3 46,XY[20] no CNA 
HD-0229 M/87 MP-CMML2 no p.Gln1191X no no no no no no no no na no no 1 46,XY[20] no CNA
HD-0257 F/71 MP-CMML1 no no no no no no no no no no na no p.Arg140Gln 1 46,XX[20] no CNA
HD-0272 F/79 MP-CMML1 no p.Arg1452Xp.Tyr1560LeufsX18 p.Gly646TrpfsX12 no no no no no no p. Gly13Asp na no no 3 46,XX[20] no CNA
HD-0273 M/76 MP-CMML1 no p.Gly1361Ser p.Lys888GlufsX6 no no no no no no no na no p.Arg140Gln 3 46,XY[20] no CNA
HD-0316 M/65 MP-CMML1 p.Pro425Leu na na no na na na no no no p.Asp61Tyr na na 2 46,XY[20] losses 3q22-24 (EPHB1, NEK11, MRAS…)
HD-0318 M/69 MP-CMML1 p.Arg166X no p.Gln768X na na na na no no no no na na 2 46,XY,del(20)(q11q13)[20] loss 20q11-q13
HD-0320 F/74 MP-CMML2 splicing defect p.Arg1404X p.Gly646TrpfsX12 no no no no no no no p.Ala72Thr no no 4 47,XX,+8[20] tri 8
HD-0321 M/55 MP-CMML2 p.Arg166X no p.His630ProfsX66 no no na no no no no no no no 2 46,XY[20]  loss 3p23 (GLB1, CRTAP)
HD-0322 F/61 MP-CMML1 no no no no no no no no no no no no no 0 46,XX[20] no CNA
HD-0327 F/72 MP-CMML1 p.Tyr377LeufsX223 p.Cys1193Trp p.Gly646TrpfsX12 no no no no no no p.Gly12Asp no no no 4 47,XX,+8[20] tri 8, loss 7q11 (CALN1)
HD-0366 M/78 MP-CMML1 no no p.Ser846GlnfsX5 (nc) na na na na no no no no na na 1 46,XY[20] no CNA
HD-0367 F/70 MP-CMML2 no no no no no no ITD no no no no no no 1 46,XX,inv(11)(p15q22)[20] no CNA
HD-0370 M/70 MP-CMML2 no no p.Thr1271LysfsX10 (nc) no no no no no no no no no no 1 46,XY[20] no CNA
HD-0376 F/65 MP-CMML2 no no no no no no no no no no no no no 0 46,XX,t(1;3)(p36;q21)[20] no CNA
HD-0397 F/71 MP-CMML1 no no no no no no no no no no na no no 0  46,XX[20] na
HD-0398 M/62 MP-CMML1 no no p.Gly646TrpfsX12 no no no no no no no na no no 1 47,XY,+19[17]/46,XY[3] tri 19
HD-0399 M/74 MP-CMML1 p.Ser141Leu no p.Gly646TrpfsX12 no no p.Cys396Tyr no no no no no no no 3 46,XY[20] no CNA
HD-0404 M/88 MP-CMML2 p.Arg201X p.Asn1581IlefsX17 p.His630ProfsX66 no no no no no no no na no no 3 47,XY,+21 [20] tri 21
HD-0485 M/63 MP- CMML 2 p.Arg320X p.Leu1252Pro p.Gly646TrpfsX12 no no no no no no no na no no 3 46,XY[20] no CNA
HD-0627 F/87 MP-CMML1 no no p.Arg1068X no no p.Cys404Tyr (hom) no no no no na no no 2 46,XX,del(20)(q11q13)[6]/46,XX[19] no CNA
HD-0669 M/88 MP-CMML1 no no p.Ala611ArgfsX8 no no no no no no no na no no 1 46,XY[20] no CNA
HD-0671 F/71 MP-CMML1 p.Lys110Arg no p.Tyr591X no no no no no no no na no no 2 47,XX,+19[8]/46,XX[12] loss 17q11 (NF1), tri 19
HD-0707 M/85 MP-CMML1 no no no no no p.Tyr371His no no no no na no no 1 46,XY[20] no CNA
HD-0715 M/69 MP-CMML1 no no no no no no no no no no na no no 0 46,XY[20] na
HD-0723 M/83 MP-CMML1 no no p.1213IlefsX3 no no no no no no p.Gly12Val na no p.Arg140Gln 3 46,XY[20] no CNA
HD-0178 M/88 MD-CMML1 no no no no no no no no no no no no p.Arg140Gln 1  46,XY,del(20)(q11q13)[20] loss 13q14 (RB1), 20q11-q13
HD-0197 M/59 MD-CMML1 p.Arg320X no no na na na na no no no no na na 1 46,XY[20] no CNA
HD-0206 M/73 MD-CMML2 no deletion p.Asp879GlufsX7 no no no no no no no na no p.Arg172Lys 3 46,XY[20] loss 4q24 (TET2)
HD-0230 M/83 MD-CMML1 no no p.His630ProfsX66 no no no no no no no na no no 1 46,XY[20] no CNA
HD-0242 F/82 MD-CMML1 no no no no no no no no no no na no no 0 46,XX[25] no CNA
HD-0254 F/83 MD-CMML2 no no no no no no no no no no na no no 0  46,XX[20] loss 17q11 (NF1)
HD-0271 F/82 MD-CMML1 no no p.Pro1263GlnfsX17 no no no no no no no na no no 1 46,XX[20] no CNA
HD-0280 M/78 MD-CMML1 no p.Ser1189ValfsX37 no no no no no no no no na no no 1  45,X,-Y[19]/46,XY[1] loss Y
HD-0328 M/73 MD-CMML1 no p.Gly355Asp (hom) p.Gly646TrpfsX12 no no p.Cys404Tyr no no no no no no no 3 46,XY[20] no CNA
HD-0330 M/76 MD-CMML1 p.Gly50GlnfsX4 na na na na na na no no no no na na 1 46,XY[20] no CNA
HD-0355 M/65 MD-CMML1 no p.Cys1289Phe no no no no no no no no no no no 1 46,XY[20] no CNA
HD-0372 M/60 MD-CMML1 no no no no no no no no no no no no no 0 46,XY[20] no CNA
HD-0380 F/82 MD-CMML1 no p.Gln1414X no no no no no no no no no no no 1 46,XX[20] no CNA
HD-0388 F/71 MD-CMML1 p. Met133Ile p.Leu1721PhefsX8 no no no no no no no no na no no 2 46,XX[20] no CNA
HD-0396 M/70 MD-CMML1 no p.Ser354X no no no no no no no no na no no 1 46,XY[20] no CNA
HD-0638 F/68 MD-CMML1 no p.Leu1394TrpfsX54 no no no no no no no no na no no 1 46,XX[20] no CNA
HD-0660 M/80 MD-CMML1 no no p.Arg693X no no no no no no no na no no 1 46,XY[20] no CNA
HD-0703 M/74 MD-CMML1 no no no no no no no no no no na no no 0 46,XY[20] no CNA
HD-0711 M/79 MD-CMML1 no p.Gln649X no no no no no no no no na no no 1 46,XY[20] no CNA
HD-0712 M/41 MD-CMML1 no no no no no no no no no no na no no 0 46,XY[20] no CNA
HD-0743 M/68 MD-CMML1 no no no no no no no no no no na no no 0 46,XY[20] no CNA
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Kaplan-Meier overall survival curves for all CMML patients (A) and according to ASXL1 mutational 
status (B). The number of patients at risk over time is shown beneath each panel. (C) Cumulative 
incidence of progression to acute myeloid leukaemia for all patients (C) and according to ASXL1 
mutational status (D).  
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WBC (G/L) Monocytes (G/L) Blasts (%) Monocytes (%)
HD-0176 M/42 CMML 1 no no 17.3 1.2 2 12 no none
HD-0182 F/74 CMML 1 no no 16.0 1.9 3 3 no none
HD-0200 M/71 CMML 1 no no 22 7 8 32 no TA        
HD-0201 M/86 CMML 1 nd splenomegaly 116.8 40 7 nd yes none
HD-0223 M/85 CMML 1 no no 27.9 4.9 2 18 no none
HD-0228 M/70 CMML 1 no splenomegaly hepatomegaly 32 5 5 12 no TA
HD-0229 M/87 CMML 2 yes no 16 3.2 12 22 no none
HD-0257 F/71 CMML 1 no no 16.3 2 5 17 no EPO
HD-0272 F/79 CMML 1 no no 10 3 3 7 no hydrea
HD-0273 M/76 CMML 2 no no 32.4 15 9 23 no TA
HD-0316 M/65 CMML 2 no no 37 5.7 15 12 no none
HD-0318 M/69 CMML 1 yes splenomegaly hepatomegaly 30 1 3 6 yes none
HD-0320 F/74 CMML 2 no no 43.5 14.5 15 16 yes none
HD-0321 M/55 CMML 2 no no 55 14.8 15 35 yes none
HD-0322 F/61 CMML 1 no no 38 3.5 3 6 no hydrea
HD-0327 F/72 CMML 1 no no 188 43 9 27 yes none
HD-0366 M/78 CMML 1 no no 13.2 4.6 3 33 no TA
HD-0367 F/70 CMML 2 yes no 64 46 14 40 no none
HD-0370 M/70 CMML 2 no splenomegaly 25.4 2.5 18 10 yes TA
HD-376 F/65 CMML 2 yes no 18 2.9 11 14 no transfusions
HD-0397 F/72 CMML 1 no no 26.5 4.7 6 45 no none
HD-0398 M/59 CMML 1 no splenomegaly 36 3 6 20 yes hydrea
HD-0399 M/74 CMML 1 no splenomegaly. 
microadenomegaly 6 2 6 30 no hydrea + EPO
HD-0404 M/89 CMML 1 no no 35 12 16 34 no none
HD-0485 M/63 CMML 2 no no 14.7 4.4 12 22 no none
HD-0627 F/86 CMML 1 no splenomegaly 41.7 10 5 28 no none
HD-0669 M/88 CMML 1 no no 28.4 6.8 8 37 no TA
HD-0671 F/71 CMML 2 no no 35.9 4.7 15 30 yes none
HD-0707 M/85 CMML 1 no no 11.8 2.25 4 28 no hydrea
HD-0715 M/69 CMML 1 no no 15 1.4 7 6 no none
HD-0723 M/83 CMML 1 no no 17.9 2.87 5 12 yes TA
HD-0178 M/88 CMML 1 no no 6.9 1.5 7 22 no none
HD-0197 M/59 CMML 1 no hepatomegaly 11.4 2.6 6 23 no none
HD-0206 M/73 CMML 2 no no 8.8 1.2 18 13 yes none
HD-0230 M/86 CMML 1 no ? no 10.4 1.78 8 20 no none
HD-0242 F/82 CMML 1 no no 6.9 1.9 5 10 no none
HD-0254 F/83 CMML 2 no no 9.1 1 13 15 no none
HD-0271 F/82 CMML 1 no no 9 1.35 6 18 no none
HD-0280 M/79 CMML 1 no no 7.1 1.3 7 18 no TA
HD-0328 M/73 CMML 1 no no 7.4 4.5 4 20 no none
HD-0330 M/76 CMML 1 no hepatomegaly 5.1 1.79 7 16 no none
HD-0355 M/65 CMML 1 yes no 4 1 7 12 no none
HD-0372 M/60 CMML 1 no no 12 1.1 4 10 no none
HD-0380 M/82 CMML 1 no splenomegaly polyadenomegaly 5.4 1.1 4 10 no none
HD-0388 F/71 CMML 1 no no 7.1 1.15 6 22 no none
HD-0396 M/79 CMML 1 no nd 10.3 2 4 11 no none
HD-0638 F/68 CMML 1 no no 5.1 1.38 8 18 no none
HD-0660 M/80 CMML 1 no microadenomegaly 6.1 1.7 5 15 no TA
HD-0703 M/74 CMML 1 no no 12.8 1.42 1 4 no none
HD-0711 M/78 CMML 1 no no 9.74 1.35 3 19 no transfusions
HD-0712 M/41 CMML 1 no no 9.8 1 3 6 no none
HD-0743 M/68 CMML 1 no no 2.8 2 7 19 no none
HD-0755 M/46 CMML 1 yes no 9.8 2.4 4 12 yes none
nd : no data
EPO: erythropoietin
TA : therapeutic abstention
MP-CMML : myeloproliferative form of chronic myelomonocytic leukaemia defined by a leukocytosis superior to 13x 109 /L 
MD-CMML : myelodysplastic form of chronic myelomonocytic leukaemia defined by a leukocytosis inferior to 13x 109 /L 
MP-CMML
MD-CMML
Supplementary Table I.  Clinical and biological features of a series of CMML.
Treatment at 
sampling
Antecedent of 
chemotherapy or 
radiotherapy
Organomegaly
Bone marrowSex/Age 
(years)
Diagnosis 
(WHO)
Acute 
transformation
Peripheral blood
Patient
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